ADPKD
ADPKD
Part of NephTimes
Advertisement
Victoria SochaADPKD | May 26, 2025
The race of patients with ADPKD affects waitlist experience, allograft quality, and post-transplant outcomes, a study found.
Read More
Victoria SochaADPKD | May 23, 2025
A study of real-world data found that tolvaptan reduced long-term kidney function decline in ADPKD.
Freely FilteredADPKD | June 11, 2025
This Freely Filtered episode discusses the KDIGO guideline draft for autosomal dominant polycystic kidney disease (ADPKD).
Charlotte RobinsonADPKD | May 2, 2025
Novartis will acquire Regulus Therapeutics, developer of ADPKD therapeutic candidate farabursen, a novel oligonucleotide.
Charlotte RobinsonADPKD | June 13, 2025
Lupin's generic tolvaptan tablets are now FDA-approved for treating autosomal dominant polycystic kidney disease (ADPKD).
Charlotte RobinsonADPKD | June 13, 2025
KDIGO has published its first guideline on the evaluation, management, and treatment of ADPKD.
Victoria SochaADPKD | June 13, 2025
A study examined the effects of adding dapagliflozin to treatment with tolvaptan in patients with ADPKD.
Charlotte RobinsonADPKD | June 13, 2025
A study examined whether serum phosphate levels could predict kidney outcomes in patients with ADPKD. 
Charlotte RobinsonADPKD | June 13, 2025
An exploratory pilot study aimed to identify and evaluate potential proinflammatory biomarkers in patients with ADPKD.
Charlotte RobinsonADPKD | June 13, 2025
A post hoc analysis of TEMPO 3:4 results examined longer-term effects of tolvaptan on TKV and eGFR in patients with ADPKD.
Charlotte RobinsonADPKD | June 13, 2025
Data regarding mortality specific to patients with autosomal dominant polycystic kidney disease (ADPKD) are limited.
Charlotte RobinsonADPKD | June 13, 2025
A team evaluated the Mayo imaging classification system's ability to predict kidney outcomes in an ADPKD cohort.
Victoria SochaADPKD | April 8, 2024
Researchers compared factors associated with intracranial aneurysm in patients with ADPKD.
Charlotte RobinsonADPKD | April 3, 2024
The FDA granted orphan drug designation to AP303 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Charlotte RobinsonADPKD | April 2, 2024
Nephrologist Ronald Perrone, MD, has joined the clinical advisory board of XORTX Therapeutics, Inc.
Charlotte RobinsonADPKD | April 1, 2024
The FDA approved a clinical trial of VX-407 to treat autosomal dominant polycystic kidney disease.
Victoria SochaADPKD | March 11, 2024
Researchers examined the association between good nutritional status and preservation of kidney function in ADPKD.
Victoria SochaADPKD | February 8, 2024
Unilateral nephrectomy resulted in a decrease of 46.4% in urinary EGF excretion, and a decrease of 35.2% in eGFR.
Victoria SochaADPKD | February 5, 2024
Patients with autosomal dominant polycystic kidney disease commonly progress to ESRD in the fifth decade of life.
Victoria SochaADPKD | February 5, 2024
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the accumulation of fluid-filled cysts in the kidney
Advertisement
Advertisement
Latest News

June 19, 2025